UPDATED Jul 03, 2022
The market has not yet priced in the high-growth prospects for these companies, featuring low PEG ratio (less than 0.5), high future growth outlook and good value on the Snowflake.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
DBANDeutsche Beteiligungs | €33.50 | 0% | 0% | €465.4m | €63.72 | PE6.1x | E63.5% | 6.5% | Diversified Financials | ||
1CGCRISPR Therapeutics | US$62.73 | 3.6% | n/a | US$4.9b | US$113.38 | PE15.9x | E56.9% | n/a | Pharmaceuticals & Biotech |